Determination of serum reboxetine enantiomers in patients on chronic medication with racemic reboxetine.

@article{Ohman2003DeterminationOS,
  title={Determination of serum reboxetine enantiomers in patients on chronic medication with racemic reboxetine.},
  author={Daniel Ohman and Maria D. Cherm{\'a} and Bj{\"o}rn Norlander and Finn Bengtsson},
  journal={Therapeutic drug monitoring},
  year={2003},
  volume={25 2},
  pages={174-82}
}
The chiral compound reboxetine is used as a selective noradrenaline reuptake inhibitor (NARI) for the treatment of major depressive disorders. The pharmacokinetic variability of the enantiomers of the drug (S,S- and R,R-reboxetine) was studied using stereoselective high-performance liquid chromatography with mass spectrometric detection in a controlled clinical monotherapy situation (trial I) and a naturalistic clinical setting (trial II). Trial I included patients receiving racemic reboxetine… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

Pharmacotherapy of Depression

Humana Press • 2004
View 2 Excerpts

Similar Papers

Loading similar papers…